Liam Taylor

The investment was led by US life sciences specialist BroadOak Capital Partners, with the company’s founding investor, the Roslin Foundation, also participating.

Axol is a provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research.

The funding will accelerate Axol’s next phase of growth, supporting the expansion of its US operations and commercial presence.

It will also enable development of enhanced neuroscience, ophthalmology, and cardiovascular disease models, and cell manufacturing scale-up at its Roslin Innovation Centre base, in response to increasing global customer demand for more human-relevant in vitro disease models.

Axol Bioscience develops and supplies functional iPSC-derived cells, reagents, and specialist services to pharmaceutical, biotech, CROs and academic institutions worldwide.

Axol also provides physiologically relevant iPSC-derived models for neurodegenerative disorders including Huntington’s disease and sporadic amyotrophic lateral sclerosis (ALS/MND).

Liam Taylor, CEO of Axol Bioscience, said: “We’re proud to partner with BroadOak, a global leader in life sciences investing.

“Their expertise and support, alongside our long-term partner Roslin Foundation, reflects confidence in our long-term vision, team, products, and technology as we scale operations and expand internationally.”

Oliver Richardson, CFO, added: “Following Axol’s 45% revenue growth in 2025 and 36% in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand.”

Daniel Friedman, managing director at BroadOak Capital Partners, said: “Axol is a leader in their space and is well positioned as global regulators actively usher in the adoption of cell-based models.

“We are excited to be partnering with Liam, Oli, and the entire Axol team to support their next phase of growth.”